The generic name for Invokana is canagliflozin [1].
What is canagliflozin used for?
Canagliflozin is a medication used to treat type 2 diabetes by helping to lower blood sugar levels [1]. It also plays a role in reducing the risk of major cardiovascular events such as heart attack, stroke, or cardiovascular death in adults with type 2 diabetes and established cardiovascular disease [1]. Additionally, it is prescribed to slow the progression of diabetic kidney disease in patients with type 2 diabetes and either albuminuria or a history of cardiovascular disease [1].
How does canagliflozin work?
Canagliflozin belongs to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors [1]. It works by blocking the reabsorption of glucose in the kidneys, which leads to more glucose being eliminated from the body through urine [1]. This mechanism helps to lower blood glucose levels [1].
When does the patent for canagliflozin expire?
Information on the specific patent expiry dates for canagliflozin can be found through specialized patent tracking services [2]. These resources can provide details on various patents covering the drug and their respective expiration timelines.
Who manufactures canagliflozin?
Canagliflozin, marketed as Invokana, is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1].
Are there other drugs like canagliflozin?
Yes, other SGLT2 inhibitors are available on the market. These include dapagliflozin (Farxiga) and empagliflozin (Jardiance), which share a similar mechanism of action but may have different indications and clinical profiles [3][4][5].
What are the potential side effects of canagliflozin?
Common side effects of canagliflozin can include urinary tract infections, yeast infections of the vagina, and increased urination [1]. More serious, though less common, side effects can include dehydration, kidney problems, and diabetic ketoacidosis [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
Can canagliflozin be used for weight loss?
While some patients taking canagliflozin may experience weight loss as a side effect, it is not approved as a primary treatment for obesity [1]. Its main therapeutic uses are for managing type 2 diabetes and its associated complications [1].
*
**Sources:
1. https://www.drugpatentwatch.com/blog/invokana
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/drug/dapagliflozin
4. https://www.drugpatentwatch.com/drug/empagliflozin
5. https://www.drugpatentwatch.com/blog/invokamet